Developer docs
API playgroundTry for free, no card

Search company profiles

Schott

Full company profile

uuid002unsz

Namestring
Schott
Legal namestring
SCHOTT Poonawalla Private Limited
Company typeenum
Private
Founded yearint
1990
Descriptiontext

SCHOTT Poonawalla Private Limited, incorporated in 1994 and headquartered in Mumbai, manufactures tubular pharmaceutical glass packaging at three GMP-compliant production sites in India (Jambusar and Umarsadi in Gujarat, Baddi in Himachal Pradesh), employing more than 2,000 staff. The company is a joint venture between SCHOTT Pharma AG & Co. KGaA (Germany) — part of the SCHOTT AG group — and Indian partners, drawing on SCHOTT Pharma's globally registered FIOLAX® Type I borosilicate glass tubing and a portfolio of proprietary brands including Safepac™ ready-to-use (RTU) syringes, vials, and cartridges, CosmetiQ high-quality vials, Dual Chamber prefilled syringes, and Anti-Counterfeiting ampoules with light-emitting particle authentication.

The product portfolio spans four primary packaging formats — syringes, cartridges, vials, and ampoules — available in both bulk non-sterile configurations and pre-sterilized ready-to-use (RTU) nest-and-tub or tray formats, with regulatory certifications including ISO 15378-2017 across all three sites, ISO 13485-2016 at Umarsadi, and Drug Master Files registered for China, USA, and Canada. The company also provides professional services including DMF preparation and regulatory affairs support, analytical testing, and fill-and-finish process optimization.

Revenue is generated primarily through hardware sales of primary packaging containers to pharmaceutical manufacturers, biotech companies, and Contract Development and Manufacturing Organizations (CDMOs), with RTU sterile formats commanding premium pricing and ancillary regulatory services fees layered on. The go-to-market is sales-led and inquiry-driven, with direct enterprise engagement via the website (quote, sample, and technical inquiry forms) supported by paid digital marketing across Google, LinkedIn, Microsoft, and Meta channels, and customer relationship management through Microsoft Dynamics 365.

Short descriptiontext

SCHOTT Poonawalla manufactures Type I borosilicate glass primary pharmaceutical packaging — syringes, vials, cartridges, and ampoules — for drug manufacturers, biotech companies, and CDMOs across India and global regulated markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical glass packaging, borosilicate glass containers, prefillable syringes, pharmaceutical vials ampoules, primary containment solutions
Industry5 codes
PRIMARYIMALAEAB
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
SECONDARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)
SECONDARYIMALAIAJ
Anti-Counterfeit & Track-and-Trace Packaging (Serialization, Security Features)
NAICS code1 code
  • Glass Container Manufacturing327213
SIC code1 code
  • Glass Containers3221
Product category
Pharmaceutical Primary Packaging
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Glass Container Sales
TypeHardware Sales
Description

Sale of primary packaging solutions including prefillable syringes, cartridges, vials, and ampoules made from Type I borosilicate glass. Revenue is generated through product sales to pharmaceutical and biotech companies, with ready-to-use (RTU) sterile formats commanding premium pricing.

schott-poonawalla.com
2Regulatory Services
TypeProfessional Services
Description

Regulatory affairs support including Drug Master File (DMF) preparation, registration, and maintenance for China, USA, and Canada markets. Revenue generated through service fees supporting drug product and medical device registrations.

schott-poonawalla.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SCHOTT Poonawalla designs and manufactures primary pharmaceutical packaging made from Type I borosilicate glass (FIOLAX®) for injectable drugs, biologics, and vaccines. The portfolio includes ready-to-use (Safepac™) and bulk (StandardLine) vials, prefillable syringes (including dual-chamber), cartridges, and ampoules, complemented by regulatory services such as Drug Master File preparation for China, USA, and Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 3 million ampoules used every hour globally
Product overview1 text field

SCHOTT Poonawalla offers a comprehensive portfolio of tubular glass primary pharmaceutical packaging products manufactured in India, all made using high quality Type I Borosilicate Glass (FIOLAX®). The product range includes Safepac™ prefillable syringes (standard and dual chamber), Safepac™ cartridges and vials, StandardLine cartridges, Standard and CosmetiQ vials, and Standard and Anti-Counterfeiting ampoules. Products are available in both bulk (non-sterile) and ready-to-use (RTU) pre-sterilized configurations. The portfolio serves the pharmaceutical and biotech industries with containers for injectable drugs, supporting applications from vaccines and biologics to insulin delivery and emergency medications. SCHOTT Poonawalla also provides regulatory services including Drug Master File support and analytical services through its joint venture with SCHOTT Pharma.

Product and service9 records
1Safepac™ Glass Syringes
CategoryPharmaceutical Glass Packaging
Description

Ready-to-use prefillable glass syringes made from FIOLAX® Type I borosilicate glass, designed for high-speed fill-and-finish processing of injectable drugs, biologics, and vaccines. Available in 0.5ml–10ml volumes with staked needle, Luer Cone, and Luer Lock closure systems.

2Safepac™ Dual Chamber Syringes
CategoryPharmaceutical Glass Packaging
Description

Specialized drug delivery system with two chambers separated by a plunger and bypass for reconstituting and administering sensitive drugs (liquid-liquid or liquid-lyophilized) at point of use. Made from FIOLAX® Type I borosilicate glass in 3ml–10ml volumes.

3Safepac™ Cartridges
CategoryPharmaceutical Glass Packaging
Description

High-quality ready-to-use (RTU) medical cartridge system made from FIOLAX® clear Type I borosilicate glass, designed for hand-held injection devices such as pens and auto-injectors used with biologic drugs including insulin and GLP-1.

4Safepac™ Vials
CategoryPharmaceutical Glass Packaging
Description

Pre-washed and pre-sterilized ready-to-use (RTU) glass vials made from gold-standard FIOLAX® borosilicate glass. Available in tray, cup nest, and clip nest formats from 2R–100R for maximum flexibility at filling lines.

5StandardLine Cartridges (Bulk Cartridges)
CategoryPharmaceutical Glass Packaging
Description

Industry-leading glass cartridges made using FIOLAX® Type I borosilicate glass with high chemical resistance for drug stability. Available in 1–5 ml formats for medical pens, autoinjectors, and dental applications, supplied as bulk non-sterile containers.

6Standard and CosmetiQ Vials (Bulk Vials)
CategoryPharmaceutical Glass Packaging
Description

Pharmaceutical glass vials made from Type I borosilicate glass, available in two quality levels — Standard and CosmetiQ (tighter cosmetic Acceptable Quality Levels for sensitive or high-value pharmaceuticals). Formats from 2R–100R and 2ml–150ml with high chemical resistance for long-term drug stability.

7Standard Ampoules (Bulk Ampoules)
CategoryPharmaceutical Glass Packaging
Description

Glass ampoules made using FIOLAX® Type I borosilicate glass with high chemical resistance. Available in 1–30 ml formats with three forms (B, C, D) and three break systems (OPC, CBR, SCO), supplied as bulk non-sterile containers.

8Ampoules Anti-Counterfeiting (AC)
CategoryPharmaceutical Glass Packaging
Description

Pharmaceutical glass ampoules featuring special ink with light-emitting particles applied as identification rings, OPC dots, or printed text to protect against drug counterfeiting. Available in FIOLAX® clear and amber, 1–30 ml formats in forms B, C, or D.

9Drug Master File (DMF) Regulatory Service
CategoryRegulatory and Compliance Services
Description

Regulatory affairs service providing preparation and registration of Drug Master Files (DMFs) for China, USA, and Canada, with bilingual documentation for China and eCTD format for USA and Canada. Enables pharmaceutical customers to reference SCHOTT containment solutions in drug applications and accelerates regulatory approvals across multiple markets.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on1990-01-01
Description

SCHOTT Poonawalla is a joint venture partner with SCHOTT Pharma AG & Co. KGaA, Germany (headquartered in Mainz). Established in 1990, SCHOTT Pharma is an international technology group and one of the world's leading experts in glass parenteral packaging. The partnership provides SCHOTT Poonawalla access to SCHOTT Pharma's portfolio of innovations, regulatory expertise, and 7,000+ scientists globally. SCHOTT Poonawalla serves as SCHOTT Pharma's joint venture entity for India's pharmaceutical packaging market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

AZUR SPACE Solar Power collaborated with SCHOTT (parent company SCHOTT AG) on the development of SCHOTT® Solar Glass exos, a high-performance cover glass for next-generation space solar cells. The collaboration was supported by funding from the European Space Agency (ESA). This partnership involves SCHOTT AG, not specifically SCHOTT Poonawalla.

Strategic tierMinorTypeOthers
Description

The European Space Agency provided funding support for the development of SCHOTT® Solar Glass exos, a high-performance cover glass for space solar cells developed by SCHOTT in collaboration with AZUR SPACE. Note: This is a SCHOTT AG partnership, not SCHOTT Poonawalla specifically.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

German parent entity and global specialist in pharmaceutical glass packaging producing vials, ampoules, syringes, and cartridges from FIOLAX® tubing. As SCHOTT Poonawalla's parent JV partner, it is the most direct comparable globally with a broader geographic footprint.

TypeBroad incumbent
Description

Global medical technology company with a large pharmaceutical systems segment producing prefilled syringes, vials, and drug delivery devices. A broader incumbent whose Pharmaceutical Systems unit competes directly with SCHOTT Poonawalla in primary injectable containment.

TypeBroad incumbent
Description

Global supplier of dispensing systems, drug delivery, and active material science solutions for pharma, including elastomeric components and prefilled syringe systems. A broader incumbent with overlapping primary packaging/delivery exposure.

4Corning Incorporated
TypeEmerging player
Description

US-based specialty glass and ceramics manufacturer with Corning Pharmaceutical Technologies producing Valor® glass vials designed to reduce particle contamination and breakage. Competes in premium pharmaceutical glass vials, directly adjacent to SCHOTT Poonawalla's offerings.

TypeDirect peer
Description

Italian producer of glass and plastic primary packaging for the pharmaceutical industry, including vials, bottles, ampoules, and syringes. Directly competes with SCHOTT Poonawalla's tubular glass portfolio serving European and global pharma customers.

TypeBroad incumbent
Description

US-based manufacturer of primary packaging and delivery systems for injectable drugs, including stoppers, seals, syringes, and cartridges. Comparable primary containment offering for pharma/biotech customers with broader drug delivery portfolio.

7Nipro Corporation
TypeDirect peer
Description

Japanese medical device and pharmaceutical packaging manufacturer producing glass vials, ampoules, and prefilled syringes. Operates similar Type I borosilicate glass container lines and serves overlapping pharma and biotech customers globally.

TypeDirect peer
Description

German-headquartered global manufacturer of primary packaging glass and plastic containers for pharma, including vials, ampoules, syringes, and cartridges. Directly competes with SCHOTT Poonawalla for the same pharmaceutical and biotech customers with similar tubular glass processing capabilities.

TypeDirect peer
Description

Italian-based provider of pharmaceutical containment solutions including glass vials, syringes, and drug delivery systems. Competes head-to-head with SCHOTT Poonawalla in primary injectable packaging and offers comparable RTU/sterile formats to global pharma customers.

TypeRegional player
Description

India's largest glass container manufacturer producing pharmaceutical glass vials, bottles, and ampoules. Indian regional peer with overlapping domestic pharma customer base and similar tubular glass processing capabilities for injectables.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance14 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Schott

Pharmaceutical Primary Packagingschott-poonawalla.com

SCHOTT Poonawalla manufactures Type I borosilicate glass primary pharmaceutical packaging — syringes, vials, cartridges, and ampoules — for drug manufacturers, biotech companies, and CDMOs across India and global regulated markets.

What Schott does

SCHOTT Poonawalla Private Limited, incorporated in 1994 and headquartered in Mumbai, manufactures tubular pharmaceutical glass packaging at three GMP-compliant production sites in India (Jambusar and Umarsadi in Gujarat, Baddi in Himachal Pradesh), employing more than 2,000 staff. The company is a joint venture between SCHOTT Pharma AG & Co. KGaA (Germany) — part of the SCHOTT AG group — and Indian partners, drawing on SCHOTT Pharma's globally registered FIOLAX® Type I borosilicate glass tubing and a portfolio of proprietary brands including Safepac™ ready-to-use (RTU) syringes, vials, and cartridges, CosmetiQ high-quality vials, Dual Chamber prefilled syringes, and Anti-Counterfeiting ampoules with light-emitting particle authentication.

The product portfolio spans four primary packaging formats — syringes, cartridges, vials, and ampoules — available in both bulk non-sterile configurations and pre-sterilized ready-to-use (RTU) nest-and-tub or tray formats, with regulatory certifications including ISO 15378-2017 across all three sites, ISO 13485-2016 at Umarsadi, and Drug Master Files registered for China, USA, and Canada. The company also provides professional services including DMF preparation and regulatory affairs support, analytical testing, and fill-and-finish process optimization.

Revenue is generated primarily through hardware sales of primary packaging containers to pharmaceutical manufacturers, biotech companies, and Contract Development and Manufacturing Organizations (CDMOs), with RTU sterile formats commanding premium pricing and ancillary regulatory services fees layered on. The go-to-market is sales-led and inquiry-driven, with direct enterprise engagement via the website (quote, sample, and technical inquiry forms) supported by paid digital marketing across Google, LinkedIn, Microsoft, and Meta channels, and customer relationship management through Microsoft Dynamics 365.

Schott firmographics

Firmographics
Name
Schott
Legal name
SCHOTT Poonawalla Private Limited
Website
https://schott-poonawalla.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
SCHOTT Poonawalla manufactures Type I borosilicate glass primary pharmaceutical packaging — syringes, vials, cartridges, and ampoules — for drug manufacturers, biotech companies, and CDMOs across India and global regulated markets.
Ownership category
akta.pro rank

Schott industry classification

Industry
Product category
Pharmaceutical Primary Packaging
NAICS
Glass Container Manufacturing (327213)
SIC
Glass Containers (3221)
akta.pro industry
PRIMARYIMALAEAB
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
SECONDARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)
SECONDARYIMALAIAJ
Anti-Counterfeit & Track-and-Trace Packaging (Serialization, Security Features)

Keywords

  • Pharmaceutical glass packaging
  • Borosilicate glass containers
  • Prefillable syringes
  • Pharmaceutical vials ampoules
  • Primary containment solutions

Where Schott is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Schott business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

  1. Pharmaceutical Glass Container Sales: Sale of primary packaging solutions including prefillable syringes, cartridges, vials, and ampoules made from Type I borosilicate glass. Revenue is generated through product sales to pharmaceutical and biotech companies, with ready-to-use (RTU) sterile formats commanding premium pricing.
  2. Regulatory Services: Regulatory affairs support including Drug Master File (DMF) preparation, registration, and maintenance for China, USA, and Canada markets. Revenue generated through service fees supporting drug product and medical device registrations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Schott product offering

Product offering

Core offering

SCHOTT Poonawalla designs and manufactures primary pharmaceutical packaging made from Type I borosilicate glass (FIOLAX®) for injectable drugs, biologics, and vaccines. The portfolio includes ready-to-use (Safepac™) and bulk (StandardLine) vials, prefillable syringes (including dual-chamber), cartridges, and ampoules, complemented by regulatory services such as Drug Master File preparation for China, USA, and Canada.

Product overview

SCHOTT Poonawalla offers a comprehensive portfolio of tubular glass primary pharmaceutical packaging products manufactured in India, all made using high quality Type I Borosilicate Glass (FIOLAX®). The product range includes Safepac™ prefillable syringes (standard and dual chamber), Safepac™ cartridges and vials, StandardLine cartridges, Standard and CosmetiQ vials, and Standard and Anti-Counterfeiting ampoules. Products are available in both bulk (non-sterile) and ready-to-use (RTU) pre-sterilized configurations. The portfolio serves the pharmaceutical and biotech industries with containers for injectable drugs, supporting applications from vaccines and biologics to insulin delivery and emergency medications. SCHOTT Poonawalla also provides regulatory services including Drug Master File support and analytical services through its joint venture with SCHOTT Pharma.

Differentiator

Problem solved

Functional benefit

Products and services

  • Safepac™ Glass Syringes Ready-to-use prefillable glass syringes made from FIOLAX® Type I borosilicate glass, designed for high-speed fill-and-finish processing of injectable drugs, biologics, and vaccines. Available in 0.5ml–10ml volumes with staked needle, Luer Cone, and Luer Lock closure systems.
  • Safepac™ Dual Chamber Syringes Specialized drug delivery system with two chambers separated by a plunger and bypass for reconstituting and administering sensitive drugs (liquid-liquid or liquid-lyophilized) at point of use. Made from FIOLAX® Type I borosilicate glass in 3ml–10ml volumes.
  • Safepac™ Cartridges High-quality ready-to-use (RTU) medical cartridge system made from FIOLAX® clear Type I borosilicate glass, designed for hand-held injection devices such as pens and auto-injectors used with biologic drugs including insulin and GLP-1.
  • Safepac™ Vials Pre-washed and pre-sterilized ready-to-use (RTU) glass vials made from gold-standard FIOLAX® borosilicate glass. Available in tray, cup nest, and clip nest formats from 2R–100R for maximum flexibility at filling lines.
  • StandardLine Cartridges (Bulk Cartridges) Industry-leading glass cartridges made using FIOLAX® Type I borosilicate glass with high chemical resistance for drug stability. Available in 1–5 ml formats for medical pens, autoinjectors, and dental applications, supplied as bulk non-sterile containers.
  • Standard and CosmetiQ Vials (Bulk Vials) Pharmaceutical glass vials made from Type I borosilicate glass, available in two quality levels — Standard and CosmetiQ (tighter cosmetic Acceptable Quality Levels for sensitive or high-value pharmaceuticals). Formats from 2R–100R and 2ml–150ml with high chemical resistance for long-term drug stability.
  • Standard Ampoules (Bulk Ampoules) Glass ampoules made using FIOLAX® Type I borosilicate glass with high chemical resistance. Available in 1–30 ml formats with three forms (B, C, D) and three break systems (OPC, CBR, SCO), supplied as bulk non-sterile containers.
  • Ampoules Anti-Counterfeiting (AC) Pharmaceutical glass ampoules featuring special ink with light-emitting particles applied as identification rings, OPC dots, or printed text to protect against drug counterfeiting. Available in FIOLAX® clear and amber, 1–30 ml formats in forms B, C, or D.
  • Drug Master File (DMF) Regulatory Service Regulatory affairs service providing preparation and registration of Drug Master Files (DMFs) for China, USA, and Canada, with bilingual documentation for China and eCTD format for USA and Canada. Enables pharmaceutical customers to reference SCHOTT containment solutions in drug applications and accelerates regulatory approvals across multiple markets.

Quantifiable outcome

  • Over 3 million ampoules used every hour globally

Companies that use Schott

Customer profile

Segments2 records

Ideal customer profiles2 records

Schott technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Schott partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • SCHOTT Pharma AG & Co. KGaAcoreStrategic or Co-development Partner · 1 January 1990SCHOTT Poonawalla is a joint venture partner with SCHOTT Pharma AG & Co. KGaA, Germany (headquartered in Mainz). Established in 1990, SCHOTT Pharma is an international technology group and one of the world's leading experts in glass parenteral packaging. The partnership provides SCHOTT Poonawalla access to SCHOTT Pharma's portfolio of innovations, regulatory expertise, and 7,000+ scientists globally. SCHOTT Poonawalla serves as SCHOTT Pharma's joint venture entity for India's pharmaceutical packaging market.
  • AZUR SPACE Solar PowerminorStrategic or Co-development PartnerAZUR SPACE Solar Power collaborated with SCHOTT (parent company SCHOTT AG) on the development of SCHOTT® Solar Glass exos, a high-performance cover glass for next-generation space solar cells. The collaboration was supported by funding from the European Space Agency (ESA). This partnership involves SCHOTT AG, not specifically SCHOTT Poonawalla.
  • European Space Agency (ESA)minorOthersThe European Space Agency provided funding support for the development of SCHOTT® Solar Glass exos, a high-performance cover glass for space solar cells developed by SCHOTT in collaboration with AZUR SPACE. Note: This is a SCHOTT AG partnership, not SCHOTT Poonawalla specifically.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Schott competitors and assessment

Company assessment

Broad incumbents

  • SCHOTT Pharma AG & Co. KGaA: German parent entity and global specialist in pharmaceutical glass packaging producing vials, ampoules, syringes, and cartridges from FIOLAX® tubing. As SCHOTT Poonawalla's parent JV partner, it is the most direct comparable globally with a broader geographic footprint.
  • Becton, Dickinson and Company (BD): Global medical technology company with a large pharmaceutical systems segment producing prefilled syringes, vials, and drug delivery devices. A broader incumbent whose Pharmaceutical Systems unit competes directly with SCHOTT Poonawalla in primary injectable containment.
  • AptarGroup: Global supplier of dispensing systems, drug delivery, and active material science solutions for pharma, including elastomeric components and prefilled syringe systems. A broader incumbent with overlapping primary packaging/delivery exposure.
  • West Pharmaceutical Services: US-based manufacturer of primary packaging and delivery systems for injectable drugs, including stoppers, seals, syringes, and cartridges. Comparable primary containment offering for pharma/biotech customers with broader drug delivery portfolio.

Emerging players

  • Corning Incorporated: US-based specialty glass and ceramics manufacturer with Corning Pharmaceutical Technologies producing Valor® glass vials designed to reduce particle contamination and breakage. Competes in premium pharmaceutical glass vials, directly adjacent to SCHOTT Poonawalla's offerings.

Direct peers

  • Bormioli Pharma: Italian producer of glass and plastic primary packaging for the pharmaceutical industry, including vials, bottles, ampoules, and syringes. Directly competes with SCHOTT Poonawalla's tubular glass portfolio serving European and global pharma customers.
  • Nipro Corporation: Japanese medical device and pharmaceutical packaging manufacturer producing glass vials, ampoules, and prefilled syringes. Operates similar Type I borosilicate glass container lines and serves overlapping pharma and biotech customers globally.
  • Gerresheimer AG: German-headquartered global manufacturer of primary packaging glass and plastic containers for pharma, including vials, ampoules, syringes, and cartridges. Directly competes with SCHOTT Poonawalla for the same pharmaceutical and biotech customers with similar tubular glass processing capabilities.
  • Stevanato Group: Italian-based provider of pharmaceutical containment solutions including glass vials, syringes, and drug delivery systems. Competes head-to-head with SCHOTT Poonawalla in primary injectable packaging and offers comparable RTU/sterile formats to global pharma customers.

Regional players

  • Hindusthan National Glass & Industries (HNG): India's largest glass container manufacturer producing pharmaceutical glass vials, bottles, and ampoules. Indian regional peer with overlapping domestic pharma customer base and similar tubular glass processing capabilities for injectables.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Schott social profiles

Digital presence

Schott compliance and trust

Trust signal

Compliance14 records

Schott financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Schott leadership team

Management profile

Number of profiles

Profiles4 records

Schott funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Schott M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Schott

What does Schott do?

SCHOTT Poonawalla designs and manufactures primary pharmaceutical packaging made from Type I borosilicate glass (FIOLAX®) for injectable drugs, biologics, and vaccines. The portfolio includes ready-to-use (Safepac™) and bulk (StandardLine) vials, prefillable syringes (including dual-chamber), cartridges, and ampoules, complemented by regulatory services such as Drug Master File preparation for China, USA, and Canada.

Is Schott a public or private company?

Schott is a private company. It is classified as corporate owned and is currently operating.

When was Schott founded?

Schott was founded in 1990. It employs 1,001 to 5,000 people.

Where is Schott based?

Schott is headquartered in Mumbai, India, in the Asia region.

How does Schott make money?

Two revenue lines are on record. Pharmaceutical Glass Container Sales are the primary driver. The others are regulatory Services.

Who are Schott's main competitors?

Broad incumbents on record are SCHOTT Pharma AG & Co. KGaA, Becton, Dickinson and Company (BD), AptarGroup and West Pharmaceutical Services. Corning Incorporated is listed as an emerging player. Direct peers are Bormioli Pharma, Nipro Corporation, Gerresheimer AG and Stevanato Group. Hindusthan National Glass & Industries (HNG) is listed as a regional player.

Does Schott have an API?

No public API is recorded for Schott.

What industry is Schott in?

Schott's product category is Pharmaceutical Primary Packaging. Its primary akta.pro industry code is IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes), with a secondary code of IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules). Its NAICS code is 327213 and its SIC code is 3221.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech in AsiaMeta helps drive AR smart glasses shipments up 98%Global AR smart glasses shipments rose 98% in 2025, with second-half shipments up 148% year over year, according to Counterpoint Research. Meta holds 75.7% of the global AR glasses market, while Chinese brands have launched new models. Waveguide glasses shipments grew over 600% in 2025, with about 70% AI-enabled.YicaiglobalClimate Action Is Becoming a Key to Competing Globally, Experts Say at Shanghai Climate WeekAt Shanghai Climate Week, experts said climate action is becoming a new passport for global competition as regulators and buyers tighten supply-chain emission scrutiny. The EU's Carbon Border Adjustment Mechanism now requires exporters to account for embedded carbon, and 10 climate tech solutions were unveiled, including Wanhua Chemical's process cutting production cycles to 20 hours.openPR.comWhy Top Pharma Companies Are Investing in Parenteral Packaging Industry Sectors in 2025DataM Intelligence released a market research report on the parenteral packaging market for 2025, covering growth drivers, segmentation, and regional trends. The report notes a rebound in global packaging M&A in July 2025, with four deals involving parenteral packaging, and highlights investments by Corning and SCHOTT in India. North America is projected to lead growth through 2032.LinkedInUnited States Glass Medicine Bottles Market: Key HighlightsA market report forecasts the United States glass medicine bottles market to grow from USD 3.45 billion in 2024 to USD 5.67 billion by 2033, driven by demand for sustainable packaging and biotech applications. Key industry players such as Gerresheimer, Schott, and Ardagh Group are investing in R&D for smart and tamper-evident solutions to meet stringent FDA regulations. The report highlights opportunities in IoT-enabled smart bottles and eco-friendly designs amidst challenges like high manufacturing costs.PR NewswirePre-Sterilized/Ready to Use Pharmaceutical Packaging Market Size to Expand Lucratively and Reach $14.23 Bn to 2031 - Explained Details | Updated InsightAce StudyInsightAce Analytic Pvt. Ltd. has released a market assessment report on the global Pre-Sterilized/Ready to Use Pharmaceutical Packaging market, valued at $8.42 billion in 2022 and projected to reach $14.23 billion by 2031, growing at a CAGR of 6.13%. The report identifies increasing demand for sterile drug delivery systems, strict regulatory guidelines from agencies such as the FDA and EMA, and the surge in demand for COVID-19 vaccines as primary market drivers. Key developments highlighted include Schott's multi-billion euro investment in sterile RTU vials production in Pennsylvania in June 2022, and Stevanato's expansion of vial manufacturing under a BARDA contract in March 2022.PR NewswireGore and SCHOTT to Showcase Commercial Option for Packaging and Delivery of Silicone-Sensitive BiologicsW. L. Gore & Associates and SCHOTT have collaborated to develop and validate a silicone-free option for packaging and delivering sensitive biologics in pre-filled syringes, which they showcased at the 2019 PDA Universe of Pre-Filled Syringe and Injection Device meeting in Gothenburg, Sweden. The GORE ImproJect Plunger combined with SCHOTT's syriQ BioPure® silicone-free pre-fillable syringe eliminates silicone from both the barrel and plunger, addressing protein aggregation and inconsistent delivery issues that occur with traditional siliconized systems. Gore also presented study findings on autoinjector performance testing at the conference.GlobalprimenewsSCHOTT KAISHA to showcase its innovative range of packaging solutions at CPhI India 2017SCHOTT KAISHA will showcase its packaging solutions at CPhI India 2017 in Mumbai, launching an Opto-Electronic Inspection System for vials and its iQ platform. The company also presents nested cartridges and ready-to-use vials, aiming to improve efficiency and flexibility for pharma manufacturers.PR NewswirePrefilled Syringes Market (4th Edition), 2016 - 2026Reportlinker published a comprehensive market research report analyzing the global prefilled syringes market, projecting it to grow at an annualized rate of 3.9% between 2016 and 2026. The report identifies over 100 injectable drug products currently available in prefilled syringes and more than 65 pipeline drugs in clinical development, with North America and Europe collectively accounting for 80% of the current market share. Key market players include Becton Dickinson, Gerresheimer, SCHOTT, and Nuova Ompi, while rising adoption of biologics and integration with advanced delivery devices are cited as primary growth drivers.